Hemifacial spasm

Hemifacial spasm is a movement disorder involving involuntary contractions of muscles supplied by the facial nerve on one side of the face. It often begins around the eye and can extend to other muscles on the same side. Botulinum toxin can suppress the muscle contractions, but it does not remove an underlying facial-nerve compression or establish the cause of unilateral facial movement.

The Disorder and the Symptom Are Different Questions

Question	Reference answer
What moves?	Muscles of facial expression supplied by the ipsilateral facial nerve contract involuntarily.
What commonly underlies primary hemifacial spasm?	Neurovascular conflict near the facial nerve root exit zone is a common explanation, although anatomy and causation require specialist assessment.
Can secondary hemifacial spasm occur?	Yes. Facial-nerve injury and other structural or neurologic causes can produce a similar unilateral pattern.
What does botulinum toxin change?	It reduces signaling to selected facial muscles and provides symptomatic control; it does not decompress the facial nerve.

Diagnosis is clinical and may require imaging or electrophysiologic assessment to distinguish primary from secondary causes. Other unilateral facial movements—including post-facial-palsy synkinesis, facial dystonia, motor tics, seizures, and hemimasticatory spasm—should not be collapsed into hemifacial spasm from appearance alone.

Hemifacial Spasm Is Not Blepharospasm

Feature	Hemifacial spasm	Blepharospasm
Typical distribution	Unilateral muscles supplied by one facial nerve, often beginning periocularly.	Usually bilateral eyelid closure associated with a dystonia pattern.
Treatment goal	Reduce involuntary movement across the affected side while preserving useful facial function.	Reduce involuntary eyelid closure while preserving blinking and ocular-surface protection.
Regulatory reading	Exact product wording must be checked; a VII nerve or blepharospasm label should not automatically be expanded to the whole condition.	Some U.S. products explicitly name blepharospasm, with product-specific age and population limits.

Nearby anatomy also overlaps with crow’s feet, but aesthetic line softening has a different goal, label, distribution, and outcome measure.

U.S. Product-Label Reading

Product	Relevant current U.S. wording	Hemifacial-spasm boundary
Botox	Blepharospasm associated with dystonia, including benign essential blepharospasm or VII nerve disorders, in patients 12 years and older.	Hemifacial spasm is not named as a standalone indication; claims should remain tied to the exact label wording and treated pattern.
Xeomin	Blepharospasm in adults.	The label does not name hemifacial spasm.
Dysport	Current U.S. indications include cervical dystonia, glabellar lines, and spasticity.	Hemifacial spasm and blepharospasm are not named in the current U.S. indication list.

Sources checked July 23, 2026. Published studies of these or other products can support a clinical evidence claim without changing the U.S. indication list.

Evidence and Outcome Interpretation

A 2024 systematic review and meta-analysis included 35 studies of botulinum neurotoxin for hemifacial spasm. Only two randomized trials, totaling 83 participants, compared perioral treatment with placebo; the remaining 33 studies were single-arm reports involving 2,786 participants. The literature supports symptomatic benefit, but the evidence base is dominated by observational designs and does not justify a simple product ranking.

Relevant outcomes include spasm frequency or severity, functional interference with vision and communication, quality of life, duration of symptom control, and unwanted facial weakness. These outcomes should remain separate from cure of the underlying disorder.

Functional and Safety Context

Periocular treatment can affect blinking, eyelid closure, ocular-surface protection, and eyelid position. Extending treatment across the lower face adds questions about smile symmetry, oral competence, speech, and other facial functions. The current product label remains the authority for boxed warnings, contraindications, adverse reactions, and preparation.